Floatz logo

PROSTAGLANDIN E1

Obesity Disorder

Hillel Yaffe Medical CenterSmall moleculePhase 2/3Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity Disorder cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
Royal North Shore Hospital
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB

View all 50 →

Same molecule, other indications

PROSTAGLANDIN E1 is also rated in:

erectile dysfunctionDormant
B
Indicative ·
60 / 100
View asset →
obstetric disorderDormant
B
Indicative ·
57 / 100
View asset →
stroke disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →